Raloxifeno | Seminarios de la Fundación Española de Reumatología

Article information

Resumen

El raloxifeno es un modulador selectivo de los receptores estrogénicos (SERM) derivado del grupo químico del benzotiofeno. Su acción se centra en un efecto agonista estrogénico en el hueso y el sistema cardiovascular, y antagonista en el tejido mamario y endometrial.

Es el único SERM que ha demostrado un efecto positivo en la reducción de las fracturas vertebrales, y además en la reducción del cáncer de mama y la afección cardiovascular. Estas características le confieren una especial indicación en la prevención y el tratamiento de la osteoporosis, sin los efectos indeseables de los estrógenos en la mama y en el endometrio. A diferencia de los estrógenos, no resuelve la sintomatología climatérica, y además el riesgo de trombosis venosa profunda es semejante.

El raloxifeno es un fármaco con suficiente experiencia clínica en su manejo, y es de primera línea de elección en la osteoporosis, dentro del grupo de los antirresortivos.

Palabras clave:

Raloxifeno

Osteoporosis

Fracturas

Cáncer mama

Abstract

Raloxifene is a Selective Estrogen Receptor Modulator (SERM), derived from the Benzothiophene's chemical group. Its action focuses on an estrogenic agonist action to the bone and the cardiovascular system, and antagonist to the breast and endometrial tissue.

It is the only SERM that has proven a positive effect in diminishing vertebral fracture risk, and furthermore, reduction in breast cancer and cardiovascular pathologies. These characteristics bestow on raloxifene a special indication on osteoporosis treatment and prevention, without the undesirable effects related to the estrogen action on the breast and endometrium. The main difference to estrogens is that of it does not succeed in the climateric symptomathology and besides, yelds similar venous thrombosis risk.

Raloxifene is a pharmacy, within the antiresortive group, with enough clinical experience in its handling, such as to constitute yields as a front line pharmac on osteoporosis.

Key words:

Raloxifene

Osteoporosis

Fractures

Breast cancer

Full text is only aviable in PDF

Bibliografía

[1.]

D.P. McDonell.

Selective estrogen receptor modulators (SERMs): A firts step in the development ofr perfect hormone replacement therapy regimen.

J Soc Ginecol Investig, 7 (2000), pp. S10-S15

[2.]

P.D. Delmas, N.H. Bjarnson, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, et al.

Effects of raloxifene on bone on bone mineral density, serum cholesterol concentracions, and uterine endometrium in postmenopausal women.

N Engl J Med, 337 (1997), pp. 1641-1647

http://dx.doi.org/10.1056/NEJM199712043372301 | Medline

[3.]

B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, et al.

Reduction of vertebral fracture risk in pos menopausal women with osteoporosis treated with raloxifene: results from a 3-years randomized cli Knickerbocker RK, Nickelsen T, Genant HK et alnical trial. Multiples outcomes of raloxifene evaluation (MORE) Investigators.

JAMA, 282 (1999), pp. 637-645

Medline

[4.]

O. Johnell, W. Scheele, Y. Lu, et al.

Effects of raloxifene (RLX) Alendronate (ALN) and RLX+ALNon bonemineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis (abstract).

J Bone Miner Res, 14 (1999), pp. S157

[5.]

E.G. Lufkin, M.D. Whitaker, T. Nickelsen, et al.

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.

J Bone Miner Res, 13 (1998), pp. 1747-1754

http://dx.doi.org/10.1359/jbmr.1998.13.11.1747 | Medline

[6.]

P.J. Meunier, E. Vignot, P. Garnero, et al.

Treatment of postmenopausal women with osteoporosis or low bone mineral density with raloxifen.

Osteoporosis Int, 10 (1999), pp. 330-336

[7.]

K.M. Prestwood, M. Guness, D.B. Muchmore, Y. Lu, M. Wong, L.G. Raisz.

A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.

J Clin Endocrinol Metab, 85 (2000), pp. 2197-2202

http://dx.doi.org/10.1210/jcem.85.6.6654 | Medline

[8.]

P. Sambrook, P. Geusens, V. Keraudren, K. Gaines, A. Leung, M. Melton.

Efficacy of Fosamax vs. Evista comparison trial (effect-international): Results at 6 months [abstract].

Calcif Tissue Int, 72 (2003),

[9.]

C.C. Jhonston, N.H. Bjarnason, F.J. Cohen, A. Shah, R. Lindsay, B.H. Mitlak, et al.

Long term effects of raloxifene on bone mineral density, bone turnover, and serum lipids level in early postmenopausal women with osteoporosis: three year data from 2 double-blind, randomized, placebo controlled trials.

Arch Intern Med, 160 (2000), pp. 3444-3450

Medline

[10.]

Pavo I, Masanauskaite D, Rojinskaya L, Smetnik Y, Prienkava V, Melinichenko D, et al. Effects of raloxifene vs. placebo on bone mineral density (BMD) in postmenopausal women in the absence of calcium supplementation [abstract]. J Bone Miner Res. 14:S410.

[11.]

A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, J. Adachi, et al.

The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocrine Reviews, 23 (2002), pp. 524-528

http://dx.doi.org/10.1210/er.2001-4002 | Medline

[12.]

P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkar, C. Gennari, et al.

Efficacy of raloxifene on vertebral fracture risk reduction I postmenopausal women with osteoporosis: four-year result from a randomized clinical trial.

J Clin Endocrinol Metab, 87 (2002), pp. 3609-3617

http://dx.doi.org/10.1210/jcem.87.8.8750 | Medline

[13.]

P.D. Delmas, H.K. Genant, G.G. Crans, et al.

Severity of prevalent fractures and risk of subsequent vertebral and no vertebral fractures: results from the MORE trial.

Bone, 33 (2003), pp. 522-532

Medline

[14.]

J. Farrerons, G. Isaia, A. Renau, G. Grans, M. Womwn Wong, D. Thiebaud.

Effects of Raloxifene on vertebral and no vertebral fractures in postmenopausal women xifene,with osteoporosis with multiple (Greater than or equal to 2) prevalent vertebral fractures [abstract].

Calcif Tissue Int, 72 (2003),

[15.]

M. Maricic, J.D. Adachi, S. Sarkar, W. Wu, M. Wong, K.D. Harper.

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

Arch Untern Med, 162 (2002), pp. 1140-1143

[16.]

Qu. Yongming, Wong. Mayme, L. Jhon.

Stock The treatment with Raloxifene decrease the clinic vertebral fractures at six month.

Osteoporosi Int, 16 (2005), pp. S22-S46

[17.]

B. Fisher, J.P. Constantino, D.L. Wickerham, C.K. Redmon, M. Kavanah, W.M. Cronin, et al.

Tamoxifene for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

J Natl Cancer Inst, 90 (1998), pp. 1371-1388

Medline

[18.]

J.A. Cauley, L. Norton, M.E. Lippman, S. Eckert, K.A. Krueger, D.W. Purdie, et al.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year or Iresults from de MORE trial. Multiple outcomes of raloxifene evaluation.

Breast Cancer Res Treat, 65 (2001), pp. 125-134

Medline

[19.]

STAR. Prevention Study of Tamoxifene and Raloxifene in Postmenopausal Women at Incrased Risk fnvasive Breast Cancer, National Cancer Institute (NCI) and National Surgical Adjuvant Breast and Bowel Project (NSABP). [citado 8 Feb 2002] Disponible en: www.nsabp.pitt.edu/STAR/Index.html

[20.]

J.A. Cauley, S. Martino, E. Barret-Connor, et al.

Effects of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assesement: results of the Continuing Outcomes Rlevantas to Evista (CORE) trial.

Annu Meet Proc Am Soc Clin Oncol, 22 (2004), pp. A1018

[21.]

N.K. Wenger, E. Barret-Connor, P. Collins, D. Grady, M. Kornitzer, L. Mosca, et al.

Baseline characteristics of participants in the Raloxifene Ussers for The Heart (RUTH) trial.

Am J Cardiol, 90 (2002), pp. 1204-1210

Medline

[22.]

Bw. Walsh, L.H. Kuller, R.A. Wild, S. Pau, M. Farmer, J.B. Lawrence, et al.

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

J Am Med Asso, 279 (1998), pp. 144

[23.]

E. Barret-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.A. Cox, K. Hoszzowski, et al.

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from de MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

JAMA, 287 (2002), pp. 847-857

Medline

Follow us:

Subscribe to our newsletter